Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4907)
All Articles published online
|
Publishing Process of This Article
|
Dec 15, 2021 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2076-2087 [PMID: 35070043 DOI: 10.4251/wjgo.v13.i12.2076] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v13/i12/2076.htm |
| Number | Citing Articles |
| 1 |
Paula Fernández-Palanca, Tania Payo-Serafín, Beatriz San-Miguel, Carolina Méndez-Blanco, María J. Tuñón, Javier González-Gallego, José L. Mauriz. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation. Acta Pharmacologica Sinica 2023; 44(5): 1066 doi: 10.1038/s41401-022-01021-2
|
| 2 |
Mara Persano, Andrea Casadei-Gardini, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Margherita Rimini. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?. Expert Review of Anticancer Therapy 2023; 23(1): 19 doi: 10.1080/14737140.2023.2156340
|
| 3 |
Yuta Tai, Yoshifumi Morita, Mitsumasa Makino, Shinya Ida, Ryuta Muraki, Ryo Kitajima, Makoto Takeda, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Hiroya Takeuchi. A Case of Giant Hepatocellular Carcinoma Successfully Treated with Lenvatinib Followed by Parenchymal-Sparing Hepatectomy. The Japanese Journal of Gastroenterological Surgery 2023; 56(10): 547 doi: 10.5833/jjgs.2022.0104
|
| 4 |
Zhang Xuexian, Wang Ruidong, Ding Yuhan, Li Qingwei, Xiong Feng, Ren Hong, Zhang Jun, Li Wei. Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1422784
|
| 5 |
Wenbin Liu, Zhiguo Xie, Kefeng Shen, Lizhu Jiang, Chongyan Liu, Yongsheng Ge, Jihai Yu, Weidong Jia, Jinliang Ma, Hao Chen. Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma. Medical Oncology 2023; 40(9) doi: 10.1007/s12032-023-02082-x
|